Ji Won Han1, Pauline Maillard1, Danielle Harvey1, Evan Fletcher1, Oliver Martinez1, David K Johnson1, John M Olichney1, Sarah T Farias1, Sylvia Villeneuve1, William Jagust1, Dan Mungas1, Charles DeCarli2. 1. From the Department of Neurology (J.W.H., P.M., E.F., O.M., D.K.J., J.M.O., S.T.F., D.M., C.D.), Imaging of Dementia and Aging (IDeA) Laboratory (J.W.H., P.M., E.F., O.M., C.D.), and Division of Biostatistics, School of Medicine (D.H.), University of California at Davis; Department of Neuropsychiatry (J.W.H.), Seoul National University Bundang Hospital, Seoul National University, Seongnam, Republic of Korea; Douglas Mental Health University Institute (S.V.), McGill University, Montreal, Canada; and Helen Wills Neuroscience Institute (W.J.), University of California, Berkeley. 2. From the Department of Neurology (J.W.H., P.M., E.F., O.M., D.K.J., J.M.O., S.T.F., D.M., C.D.), Imaging of Dementia and Aging (IDeA) Laboratory (J.W.H., P.M., E.F., O.M., C.D.), and Division of Biostatistics, School of Medicine (D.H.), University of California at Davis; Department of Neuropsychiatry (J.W.H.), Seoul National University Bundang Hospital, Seoul National University, Seongnam, Republic of Korea; Douglas Mental Health University Institute (S.V.), McGill University, Montreal, Canada; and Helen Wills Neuroscience Institute (W.J.), University of California, Berkeley. cdecarli@ucdavis.edu.
Abstract
OBJECTIVE: To determine whether vascular and neurodegenerative factors influence cognition before clinically relevant Alzheimer disease pathology, we analyzed MRI measures and amyloid imaging in an ethnoracially diverse cohort of cognitively normal individuals older than 60 years. METHODS: Participants (n = 154; mean age 74.15 ± 6.94; 50% female; 54% Caucasian, 22.1% Hispanic, 14.9% African American) were recruited from the University of California, Davis Alzheimer's Disease Research Center, who were cognitively normal at baseline, time of PET, and MRI, and received yearly cognitive assessment for 6.23 ± 4.16 years. Mixed model regression with random slope and intercept was calculated for episodic memory and executive function, adjusting for age, sex, education, and ethnicity. RESULTS: Vascular burden score was associated with total white matter hyperintensity (WMH) volume (β, 0.171; 95% confidence interval [CI], 0.024-0.318). WMH volume was associated with low baseline executive function (-0.115; -0.226 to -0.003) and rate of change in memory (-0.029; -0.045 to -0.012). Hippocampal volume was associated with the rate of change in memory (0.040; 0.021-0.059) and executive function (0.024; 0.008-0.039). Continuous measures of amyloid status influenced change in memory (-0.026; -0.044 to -0.008) and executive function (-0.033; -0.046 to -0.021) independently of MRI measures. CONCLUSION: Vascular brain injury and neurodegeneration are associated with baseline cognitive performance and the rate of longitudinal change independent of amyloid status among community-dwelling, ethnicity diverse cognitively normal individuals, supporting the role of vascular diseases as risk factors for later-life dementia.
OBJECTIVE: To determine whether vascular and neurodegenerative factors influence cognition before clinically relevant Alzheimer disease pathology, we analyzed MRI measures and amyloid imaging in an ethnoracially diverse cohort of cognitively normal individuals older than 60 years. METHODS: Participants (n = 154; mean age 74.15 ± 6.94; 50% female; 54% Caucasian, 22.1% Hispanic, 14.9% African American) were recruited from the University of California, Davis Alzheimer's Disease Research Center, who were cognitively normal at baseline, time of PET, and MRI, and received yearly cognitive assessment for 6.23 ± 4.16 years. Mixed model regression with random slope and intercept was calculated for episodic memory and executive function, adjusting for age, sex, education, and ethnicity. RESULTS: Vascular burden score was associated with total white matter hyperintensity (WMH) volume (β, 0.171; 95% confidence interval [CI], 0.024-0.318). WMH volume was associated with low baseline executive function (-0.115; -0.226 to -0.003) and rate of change in memory (-0.029; -0.045 to -0.012). Hippocampal volume was associated with the rate of change in memory (0.040; 0.021-0.059) and executive function (0.024; 0.008-0.039). Continuous measures of amyloid status influenced change in memory (-0.026; -0.044 to -0.008) and executive function (-0.033; -0.046 to -0.021) independently of MRI measures. CONCLUSION: Vascular brain injury and neurodegeneration are associated with baseline cognitive performance and the rate of longitudinal change independent of amyloid status among community-dwelling, ethnicity diverse cognitively normal individuals, supporting the role of vascular diseases as risk factors for later-life dementia.
Authors: John C Morris; Catherine M Roe; Chengjie Xiong; Anne M Fagan; Alison M Goate; David M Holtzman; Mark A Mintun Journal: Ann Neurol Date: 2010-01 Impact factor: 10.422
Authors: Teresa Jenica Filshtein; Brittany N Dugger; Lee-Way Jin; John M Olichney; Sarah T Farias; Luis Carvajal-Carmona; Paul Lott; Dan Mungas; Bruce Reed; Laurel A Beckett; Charles DeCarli Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472
Authors: Emelia J Benjamin; Paul Muntner; Alvaro Alonso; Marcio S Bittencourt; Clifton W Callaway; April P Carson; Alanna M Chamberlain; Alexander R Chang; Susan Cheng; Sandeep R Das; Francesca N Delling; Luc Djousse; Mitchell S V Elkind; Jane F Ferguson; Myriam Fornage; Lori Chaffin Jordan; Sadiya S Khan; Brett M Kissela; Kristen L Knutson; Tak W Kwan; Daniel T Lackland; Tené T Lewis; Judith H Lichtman; Chris T Longenecker; Matthew Shane Loop; Pamela L Lutsey; Seth S Martin; Kunihiro Matsushita; Andrew E Moran; Michael E Mussolino; Martin O'Flaherty; Ambarish Pandey; Amanda M Perak; Wayne D Rosamond; Gregory A Roth; Uchechukwu K A Sampson; Gary M Satou; Emily B Schroeder; Svati H Shah; Nicole L Spartano; Andrew Stokes; David L Tirschwell; Connie W Tsao; Mintu P Turakhia; Lisa B VanWagner; John T Wilkins; Sally S Wong; Salim S Virani Journal: Circulation Date: 2019-03-05 Impact factor: 29.690
Authors: Susan M Landau; Christopher Breault; Abhinay D Joshi; Michael Pontecorvo; Chester A Mathis; William J Jagust; Mark A Mintun Journal: J Nucl Med Date: 2012-11-19 Impact factor: 10.057
Authors: C C Rowe; S Ng; U Ackermann; S J Gong; K Pike; G Savage; T F Cowie; K L Dickinson; P Maruff; D Darby; C Smith; M Woodward; J Merory; H Tochon-Danguy; G O'Keefe; W E Klunk; C A Mathis; J C Price; C L Masters; V L Villemagne Journal: Neurology Date: 2007-05-15 Impact factor: 9.910
Authors: Stéphanie Debette; Alexa Beiser; Charles DeCarli; Rhoda Au; Jayandra J Himali; Margaret Kelly-Hayes; Jose R Romero; Carlos S Kase; Philip A Wolf; Sudha Seshadri Journal: Stroke Date: 2010-02-18 Impact factor: 7.914
Authors: Clifford R Jack; Val J Lowe; Stephen D Weigand; Heather J Wiste; Matthew L Senjem; David S Knopman; Maria M Shiung; Jeffrey L Gunter; Bradley F Boeve; Bradley J Kemp; Michael Weiner; Ronald C Petersen Journal: Brain Date: 2009-03-31 Impact factor: 13.501
Authors: Shraddha Sapkota; Kelsey Erickson; Danielle Harvey; Sarah E Tomaszewski-Farias; John M Olichney; David K Johnson; Brittany N Dugger; Dan M Mungas; Evan Fletcher; Pauline Maillard; Sudha Seshadri; Claudia L Satizabal; Tiffany Kautz; Danielle Parent; Russell P Tracy; Izumi Maezawa; Lee-Way Jin; Charles DeCarli Journal: Alzheimers Dement (Amst) Date: 2022-09-01